Can a Dual-Targeting antibody stop amyloid buildup in its tracks?

This phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells producing these harmful proteins. The study will assess how well the drug works in achieving a complete response and how safe it is, using a step-up dosing schedule over several treatment cycles.